Pictor Establishes U.S. Headquarters and Scales Operations, Revolutionizing Proteomics Testing Amid Regulatory Shift
CARLSBAD, Calif., May 20, 2025 /CNW/ -- Pictor, a global leader in multiplex proteomics solutions, is excited to announce the establishment of its U.S. headquarters in Carlsbad, California, marking a significant milestone in its strategic growth and commitment to advancing cutting-edge solutions for laboratories worldwide. This transformation solidifies Pictor Holdings Inc. as the parent company, which will continue to proudly operate its subsidiaries in New Zealand, India, and Australia.
Pictor launches its U.S. operations with strong financial backing, having secured $5 million in seed funding—$3 million from its existing lead investors and $2 million from new U.S.-based investors. This investment underscores the confidence in Pictor's platform and positions the company for rapid growth in the U.S. market.
This announcement follows a landmark decision by a U.S. federal court, which struck down the FDA's plan to regulate laboratory-developed tests (LDTs). The court ruling reinforces the current regulatory framework under the Clinical Laboratory Improvement Amendments (CLIA), providing stability in the clinical industry by alleviating potentially costly operational burdens that new regulations would have imposed.
"The recent ruling ensures a clear delineation of responsibilities between CLIA and the FDA, providing solution providers like Pictor the certainty needed to equip our partners with an innovative and cost-effective platform," said Jamie Platt, CEO of Pictor Holdings Inc. "This proven regulatory landscape aligns with our ability to offer efficient, affordable proteomics tools to laboratories and healthcare providers, ensuring accessibility for all."
Empowering Labs with the Pictor Platform
Pictor's products, designed for clinical laboratory use, are poised to help laboratories capitalize on this new era of opportunity. Through its highly flexible, scalable, and cost-effective multiplex proteomics platform, Pictor enables labs to not only develop their own LDTs but also improve workflow efficiency to meet growing demands.
Key advantages of the Pictor platform include:
Price: Affordable testing made possible through its low-cost PictImager™ platform, standard detection reagents, and under $50 per sample consumable costs.
Performance: High-throughput testing achieved with the PictArray™ assays and rapid imaging, with results for 96 samples under four hours.
Productivity: A flexible solution adaptable to various sample types and capable of running up to 50 analytes per test.
Meeting the Needs of a Changing Healthcare Landscape
Anticipated reductions in CMS and Medicare spending are accelerating demand for affordable, accessible testing solutions. Pictor is uniquely positioned to meet this need with its streamlined, scalable platform that delivers unmatched price, performance, and productivity across clinical and research applications. By lowering cost barriers for clinical labs and expanding access to underserved communities, Pictor is advancing its mission to make high-quality proteomics broadly accessible in a shifting healthcare environment.
"As the founder and CEO of Mira Precision Health, I have been deeply impressed by Pictor's technology," said Sandra Gunselman, Ph.D. "The platform's flexibility allows us to respond quickly and cost-effectively to healthcare demands. Its speed, affordability, and scalability make it invaluable in advancing innovative diagnostics, particularly for underserved communities."
Leadership and Website Launch
Pictor's continued momentum is also marked by the announcement of a new Board of Directors, led by Chair Paul Kinnon, CEO Jamie Platt, and seasoned investor executive, Marko Bogoievski. Complementing this strategic leadership, Pictor has also introduced a robust executive team, including Kate Rhodes (COO), Janine McMurdie (CCO), Yoichi Furuya (CSO),and Claire Zimmerman (Director of Business Operations).
Coinciding with this announcement is the launch of Pictor's redesigned website. Designed with customer-centricity in mind, the website showcases Pictor's comprehensive testing solutions. The redesigned site provides customers with resources to learn how Pictor's solutions can help power the translation of research discoveries into clinical impact.
About Pictor
Pictor is a leader in flexible, targeted proteomics, delivering next generation multiplex solutions that empower clinical labs, diagnostic manufacturers, and veterinary providers worldwide. Powered by its patented PictArray™ platform, PictImager™, and AI-powered Pictorial™ software, Pictor delivers deeper insights from a single sample, offering faster, more affordable, and scalable results.
From infectious diseases to oncology, Pictor's innovative technology is advancing both human and animal health, enabling breakthroughs in clinical decision-making. Headquartered in San Diego, Pictor Holdings Inc. is committed to driving innovation through solutions designed for unmatched performance, cost efficiency and productivity.
Discover how Pictor is shaping the future of proteomics testing at www.pictordx.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
TORONTO, June 5, 2025 /CNW/ - iGan Partners is pleased to announce that it has led the first close of a Seed+ financing round for Cosm Medical, a medical device company modernizing pelvic health through personalized gynecological care. The round included new investor Spring Impact Capital and several angels, and will support Cosm's U.S. expansion, clinical validation, and commercial growth. Cosm's flagship platform, Gynethotics TM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime. "Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care," said Sam Ifergan, Founding Partner at iGan Partners. "We're excited to support their mission to improve outcomes and quality of life for millions of women." "At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning." – Derek Sham, Founder & CEO of Cosm Medical. "We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. "As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders. Gynethotics TM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery. About Cosm Medical Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, Gynethotics TM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at About iGan Partners iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at
Cision Canada
a day ago
- Cision Canada
Dime Community Bank Selects Quantifind to Strengthen Sanctions Screening in Payments
PALO ALTO, Calif., June 4, 2025 /CNW/ -- Dime Community Bancshares, Inc., the holding company for Dime Community Bank, a New York State-chartered trust company with over $14 billion in assets and the number one deposit market share among community banks on Greater Long Island (1), has chosen Quantifind's AI-powered risk intelligence platform to enhance its sanctions screening for payments. Faced with increasing regulatory scrutiny and growing complexity in global transactions, Dime sought a more precise and scalable solution to strengthen its compliance program while maintaining efficient operations. After a competitive evaluation, Dime selected Quantifind for its advanced capabilities in risk detection and seamless integration into existing workflows. "Our partnership with Quantifind represents a significant advancement in our compliance capabilities," said Michael Fegan, CTO, Dime Community Bank. "Quantifind's AI-driven platform equips us to protect our customers and communities while maintaining the highest standards of regulatory compliance." "We're proud to partner with Dime Community Bank and extend our support to mid-market banks that are critical to the financial ecosystem," said Graham Bailey, Quantifind COO. "Quantifind's solutions are designed to empower banks of all sizes to tackle financial crime with unparalleled speed, accuracy, and scalability." Quantifind's commitment to supporting mid-market banks reflects a broader mission to deliver purpose-built AI solutions that help institutions of all sizes detect and mitigate financial crime risks. About Dime Community Bank Dime Community Bank, headquartered in Hauppauge, New York, has served its community since 1864. With over 60 locations across the New York metropolitan area, which includes the five boroughs, Long Island, and Westchester County, Dime offers a comprehensive range of financial services for individuals and businesses. About Quantifind Quantifind is a leader in financial crime intelligence automation. Its Graphyte™ platform delivers real-time, accurate risk assessments by integrating internal data with unstructured public information, enabling organizations to uncover hidden threats and strengthen compliance with speed, accuracy, and scale. ¹ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for community banks with less than $20 billion in assets. Forward-Looking Statements Statements contained in this news release that are not historical facts are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated. Media Contact Annalisa Camarillo EVP of Marketing, Quantifind Email: [email protected] SOURCE Quantifind
Cision Canada
a day ago
- Cision Canada
Growing with Purpose: Medicus Pension Plan announces inflation increases and two valuable new benefit features for members Français
TORONTO, June 4, 2025 /CNW/ - Medicus Pension Plan ™ published its annual report today, announcing its strong funded status of 152% as of January 1, 2025, along with a robust return of 9.1% in 2024. Medicus provided 100% inflation protection for all pensions earned in 2022, 2023 and 2024, including a notable 4.0% increase for 2024, and introduced two new benefit features with extended guarantee periods to enhance security for members and their families. "Medicus has established a strong foundation that allows us to offer value to our members in many ways," says Simone Reitzes, Managing Director of the Medicus Pension Plan. "By providing inflation increases and extending guarantee periods - in response to feedback provided by our members - we can further support physicians and their families over time." Medicus was designed to meet the unique needs of physicians, including options for financial protection for members and their families. The plan now includes a 15-year guarantee period on its base pension option and all spousal pension options now have a 10-year guarantee period, in addition to the existing lifetime spousal protection. "Physicians want to focus on patients, they don't want to worry about planning for retirement. Medicus delivers a future we can count on," says Dr. Joss Reimer, the president of the Canadian Medical Association. "I look forward to seeing this available as an option to physicians across the country." Inflation increases help members keep pace with the rising cost of living and maintain the value of their pension over time. And with extended guarantee periods now included as part of every pension option, Medicus offers members certainty that no matter what happens, their family will benefit from the financial protection built into the plan. "It is inspiring to see the positive impact we're making on the financial well-being of the growing community of physicians across Canada who have chosen Medicus," adds Reitzes. Learn more here. About Medicus Tailored exclusively to the unique needs of physicians, the Medicus Pension Plan is a defined benefit multi-employer pension plan that offers the financial peace of mind that comes with a secure, predictable lifetime pension. Medicus is designed specifically for physicians, offers geographic mobility, includes physician representation on its Administrative Board, is tax effective, with contributions generally deductible to physicians' professional corporations, and has access to specialized institutional investment management because member assets are pooled in a single trust fund, allowing unique investment opportunities, risk sharing and a long-term investment horizon. Medicus is a registered pension plan. It is registered under the Pension Benefits Act (Ontario) and the Income Tax Act (Canada). To determine if Medicus is appropriate for your retirement planning needs and retirement income objectives, please consult with a financial advisor. Medicus Pension Plan ™ is a trademark used under licence. For more information, please visit About Scotiabank Scotiabank's vision is to be our clients' most trusted financial partner and deliver sustainable, profitable growth. Guided by our purpose: "for every future," we help our clients, their families and their communities achieve success through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With assets of approximately $1.4 trillion (as at January 31, 2025), Scotiabank is one of the largest banks in North America by assets, and trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit and follow us on X @Scotiabank.
